Pfizer’s Vyndaqel recommended by NICE to treat rare heart disease ATTR-CM
Pfizer’s Vyndaqel (tafamidis) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare heart disease affecting about 1,500 people in England. The drug has been …